Company / Cost of Revenue
NovaBay Pharmaceuticals, Inc. Cost of Revenue History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$3.3M
FY2024
5-year range
$3.3M / $6.6M
FY2020-FY2024
Trend
-24.5%
vs FY2023
Sector context
#74 of 83
Health Care
What the data says
NovaBay Pharmaceuticals, Inc.'s cost of revenue of $3M is lower than 89% of companies in the Health Care sector (FY2024). Cost of Revenue has fluctuated over the past 10 years, ranging from $1M in FY2015 to $7M in FY2022.
Based on SEC 10-K filings.
$3M in FY2024 with a 5-year CAGR of +13.7%.
Improved from $7M to $3M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -3.6%
- 5-Year CAGR
- +13.7%
- 10-Year CAGR
- -
Sector benchmark
Top 11% in Health CareTop 11% of 83This company $3.3M Sector average $2.0B
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of +13.7%, indicating consistent growth.
- In FY2024, cost of revenue decreased 24.5% year-over-year.
- Ranks #74 out of 83 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $3.3M | -24.5% |
| FY2023 | $4.4M | -34.0% |
| FY2022 | $6.6M | +79.5% |
| FY2021 | $3.7M | -7.1% |
| FY2020 | $4.0M | +128.4% |
| FY2019 | $1.7M | +15.6% |
| FY2018 | $1.5M | -46.0% |
| FY2017 | $2.8M | +13.0% |
| FY2016 | $2.5M | +95.4% |
| FY2015 | $1.3M | +159.5% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026